An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M by Vernallis, Ann B. et al.
An Antagonist for the Leukemia Inhibitory Factor Receptor
Inhibits Leukemia Inhibitory Factor, Cardiotrophin-1,
Ciliary Neurotrophic Factor, and Oncostatin M*
(Received for publication, June 26, 1997)
Ann B. Vernallis, Keith R. Hudson, and John K. Heath‡
From the CRC Growth Factor Group, School of Biochemistry, University of Birmingham, Edgbaston,
Birmingham B15 2TT, United Kingdom
The leukemia inhibitory factor receptor (LIF-R) is ac-
tivated not only by LIF, but also by cardiotrophin-1,
ciliary neurotrophic factor with its receptor, and on-
costatin M (OSM). Each of these cytokines induces the
hetero-oligomerization of LIF-R with gp130, a signal-
transducing subunit shared with interleukin-6 and in-
terleukin-11. The introduction of mutations into human
LIF that reduced the affinity for gp130 while retaining
affinity for LIF-R has generated antagonists for LIF. In
the current study, a LIF antagonist that was free of
detectable agonistic activity was tested for antagonism
against the family of LIF-R ligands. On cells that express
LIF-R and gp130, all LIF-R ligands were antagonized. On
cells that also express OSM receptor, OSM was not an-
tagonized, demonstrating that the antagonist is specific
for LIF-R. Ligand-triggered tyrosine phosphorylation of
both LIF-R and gp130 was blocked by the antagonist.
The antagonist is therefore likely to work by preventing
receptor oligomerization.
Functional overlap among cytokines often derives from
shared receptor components. Interleukin-6 (IL-6),1 IL-11, leu-
kemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary
neurotrophic factor (CNTF), and OSM (oncostatin M) have
biological activities in common, and all require gp130 as a
signal-transducing subunit (for review see Ref. 1). LIF (2–6),
CT-1 (7), CNTF (8, 9), and OSM (6, 10, 11) activate gp130 in
complexes with LIF receptor (LIF-R). LIF-R is a transmem-
brane signaling subunit that is structurally related to gp130
and belongs to the same hematopoietin receptor family (4).
Ligand binding drives the heterodimerization of LIF-R and
gp130, which results in inter alia activation and tyrosine phos-
phorylation of the Jak-Tyk cytoplasmic tyrosine kinases (12,
13). The Jaks in turn phosphorylate tyrosine residues in the
cytoplasmic domains of both LIF-R and gp130 (8), allowing the
recruitment of substrates with Src homology 2 domains includ-
ing STAT3 and protein tyrosine phosphatase PTP1D (14–17)
(for review see Refs. 18 and 19). CNTF weakly activates LIF-
R-gp130, becoming a potent agonist once first bound to a non-
signal-transducing subunit, CNTFRa. In addition to LIF-R-
gp130, OSM also activates a receptor complex unique to OSM
made up of OSM-R and gp130 (20). OSM-R has recently been
identified as a transmembrane signaling subunit related to
LIF-R and gp130 (20). Thus, LIF-R participates in a subset of
gp130-mediated responses that includes all known LIF, CT-1,
and CNTF responses, as well as some responses to OSM.
LIF-R is moderately expressed in testis, eye, skeletal muscle,
ovary, uterus, thymus, brain, and fat and is highly expressed in
liver and placenta (21). Activation of LIF-R-gp130 complexes
regulates the differentiation and proliferation of a variety of
cell lines as well as influencing the behavior of cultured neu-
rons, hepatocytes, and adipocytes (for review see Ref. 22). Gene
knockout experiments have demonstrated roles for LIF-R in
development. LIF-R2/2 and CNTFRa2/2 mice show a sub-
stantial loss of motor neurons (23, 24). LIF-R2/2 mice have
also been reported to suffer poor placentation, severe bone
abnormalities, metabolic defects, and a reduction in the num-
ber of astrocytes (25). LIF-R2/2 and CNTFRa2/2 mice die
perinatally. LIF-R ligands have also been implicated in post-
natal pathology, including breast cancer (26), rheumatoid ar-
thritis (27), inflammation (28, 29), giant cell arteritis (30), liver
(31) and muscle regeneration (32), glial responses to central
nervous system lesions (33, 34), and peripheral nerve injury
(35–40). Determining the precise role of LIF-R activation in
each of these processes is of considerable clinical interest.
An antagonist for all LIF-R ligands would be useful in defin-
ing the function of LIF-R in vivo, especially in situations in
which the LIF-R ligand has not been identified or more than
one is present. Neutralizing the currently known ligands may
be insufficient, because novel LIF-R ligands are likely to be
identified in the future (23). A LIF-R antagonist would also be
useful in dissecting OSM responses according to receptor usage
and might have therapeutic applications in pathologies such as
multiple myeloma (41).
One approach to designing a LIF-R antagonist is to block the
heterodimerization of LIF-R and gp130. Mutant LIF molecules
with reduced gp130 binding will occupy LIF-R but will be
impaired in receptor complex formation. We recently described
the generation of LIF antagonists with reduced affinity for
gp130 (42). Using binding assays to the purified extracellular
domains of human gp130 (hgp130) and human LIF-R (hLIF-R),
we showed that the antagonists bound to hLIF-R with wild-
type affinity (KD 5 ;1 nM (4, 43)) but did not bind detectably to
hgp130 (wild type affinity for gp130 is 100–1000-fold lower
than to LIF-R (42, 44)), a finding that is consistent with topo-
logically discrete receptor binding sites. One of the antagonists,
hLIF-05, which carries the simultaneous substitution of four
residues in the A helix and five residues in the C helix (A117E,
D120R, I121K, G124N, S127L, Q25L, S28E, Q32A, and S36K),
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is free of any residual agonistic activity. In proliferation assays
on the Ba/F3-hLIF-R-hgp130 cell line, hLIF-05 showed no stim-
ulatory activity when presented alone and successfully antag-
onized hLIF when presented at excess to hLIF (42). Results
presented here demonstrate that hLIF-05 is a true LIF-R an-
tagonist that will antagonize responses to all currently identi-
fied LIF-R ligands, including hLIF, murine CT-1 (mCT-1), hu-
man CNTF (hCNTF), and human OSM (hOSM). We further
show that hLIF-05 discriminates between hLIF-R and human
OSM-R (hOSM-R). Receptor phosphorylation assays demon-
strate that hLIF-05 blocks tyrosine phosphorylation of hLIF-R
and hgp130, which suggests that hLIF-05 blocks receptor acti-
vation and signal transduction.
EXPERIMENTAL PROCEDURES
Cells, Cytokines, and Antibodies—Ba/F3-hLIF-R-hgp130 cells are
Ba/F3 cells stably transfected with the transmembrane forms of hgp130
and hLIF-R (45). They were grown in RPMI (Life Technologies, Inc.),
supplemented with glutamine (2 mM), penicillin (50 IU/ml) streptomy-
cin (50 mg/ml), 10% fetal calf serum, and 20 ng/ml hLIF. The HepG2 cell
line, obtained from the William Dunn School of Pathology (Oxford), and
the IMR 32 neuroblastoma cell line, obtained from the European Col-
lection of Animal Cell Cultures, were cultured in Dulbecco’s modified
Eagle’s medium/F-12 1:1, glutamine, penicillin, streptomycin, 10% fetal
calf serum. 293/tsA1609neo (293T) cells are a transformed epithelial
kidney cell line that produces SV40 large T antigen (46). 293T cells were
cultured in Dulbecco’s modified Eagle’s medium, glutamine, penicillin,
streptomycin, 10% fetal calf serum.
hLIF and hLIF-05 were produced in Escherichia coli JM109 as de-
scribed previously (42, 45, 47). hOSM was produced as a glutathione
S-transferase fusion protein that has a recognition site for human
rhinovirus protease 3C (HRV3C) (48, 49) inserted in place of the throm-
bin site.2 hOSM was purified in the same manner as hLIF, except that
in place of thrombin, HRV3C tagged with six tandem histidine residues
was applied as the protease. The HRV3C tagged with histidine was
produced in the expression vector pTrcHisA (Invitrogen) and purified
on nickel-chelating resin. mCT-1 was a gift from Diane Pennica
(Genentech, Inc). Recombinant hCNTF produced in bacteria was a gift
from Ralph Laufer (Istituto di Ricerche di Biologia Molecolare P. An-
geletti). A serum-free culture medium of baculovirus-infected Hi-5 in-
sect cells expressing c-myc-tagged soluble CNTFRa (;2 mg/liter) (50)
was kindly provided by Giacomo Paonessa (Istituto di Ricerche di Bio-
logia Molecolare P. Angeletti).
Rabbit anti-LIF-R-Fc was raised against a portion of the extracellu-
lar domain of human LIF-R (amino acids 2–538) fused to the Fc region
of human IgG1 (42). Antibodies were purified on protein A-Sepharose
(Pharmacia Biotech Inc.) and used directly or coupled to protein A-
Sepharose with dimethylpimelimidate (51). Sheep anti-LIF-R was gen-
erated by The Binding Site Limited. The immunogen was the same as
for the rabbit serum except that the receptor was purified by cleavage
away from the Fc region via a HRV3C site that had been inserted
between the LIF-R and the Fc region by expressing the fusion in a
modified pIG-1 vector.2 Goat anti-human gp130 was purchased from
R & D Systems. Rabbit anti-human gp130 and anti-phosphotyrosine
(clone 4G10) were purchased from Upstate Biotechnology Incorporated.
The secondary antibodies, donkey anti-rabbit Ig peroxidase-linked spe-
cies-specific F(ab9)2 fragment and sheep anti-mouse Ig peroxidase-
linked species-specific F(ab9)2 fragment were purchased from Amer-
sham Corp. Affinity purified donkey anti-Sheep IgG, peroxidase-linked,
was purchased from The Binding Site Limited.
Biological Assays—Proliferation assays on Ba/F3-hLIF-R-hgp130
were carried out as described previously except that 4-fold successive
dilutions of the cytokines were applied to the washed cells (45). Cell
proliferation was assessed by 3-(4,5-dimethyl thiazol-2yl)-2,5-diphenyl
tetrazolium bromide (Sigma) staining (52).
HepG2 cells were stimulated in triplicate as described except that for
the first 24-h period the induction medium contained 1 mM dexametha-
sone (Sigma) and 1% heat-inactivated fetal calf serum. Recombinant
factors were presented during the second 24-h period in the same
medium. Acute-phase protein production was assessed by an enzyme-
linked immunosorbent assay for secreted haptoglobin (53).
IMR 32 cells were transiently transfected by the calcium phosphate
method (54) with pVIPCAT1 (55) (a kind gift from Richard H. Goodman;
Tufts New England Medical Center) and Rous sarcoma virus-b-Gal in
an assay analagous to that described by Johnson and Nathanson (56).
After transfection, the cells were washed, and medium containing the
factors was added. Following 24 h of stimulation, the cells from tripli-
cate wells were combined and lysed. Chloramphenicol acetyltransferase
and b-Gal in the lysates were measured by enzyme-linked immunosor-
bent assay (Boehringer Mannheim).
Phosphorylation Assays—293T cells were transiently transfected by
calcium phosphate (54) with hLIFR subcloned into PXMT2, a derivative
of pXM (57) and with hgp130 (from T. Kishimoto; Osaka University
Medical School) subcloned into pcDNA3.1 (Invitrogen). Transfected
cells were washed and allowed 48 h for expression. Following serum
starvation for 4 h, 293T cells were treated with medium alone, with
medium containing hLIF (0.5 nM), with hLIF (0.5 nM) plus hLIF-05 (500
nM), or with hLIF-05 (500 nM) alone for 15 min. Cells were lysed using
the buffer described by Bellido et al. (58), except that 50 mM Tris, pH
8.0, was substituted for 20 mM, pH 7.5, and 0.5% Nonidet P-40 (Boeh-
ringer Mannheim) was substituted for 1% Brij96. Lysates were cleared
of insoluble material and then divided into two portions. One portion
was precleared on protein A-Sepharose and then incubated overnight at
4 °C with rabbit anti-LIF-R-Fc coupled to protein A-Sepharose. The
second portion was precleared on protein G-Sepharose (Pharmacia) and
then incubated with protein G-Sepharose coated with goat anti-human
gp130.
Immunoprecipitated protein/Sepharose beads were washed in lysis
buffer. Bound protein was eluted in electrophoresis sample buffer and
separated on SDS-polyacrylamide gels (4–15% precast gel, Bio-Rad
Laboratories Inc.), immunoblotted onto Immobilon P (polyvinylidene
difluoride) (Millipore), and blocked as described (58). SDS-polyacryl-
amide gels were run in duplicate so that each sample could be analyzed
for both phosphotyrosine containing proteins and receptor recovery.
Sheep anti-LIF-R and rabbit anti-gp130 were used as probes for recep-
tor recovery. Immunoblots were developed with SuperSignal Substrate
(Pierce).
HepG2 cells were handled in the same manner as the 293Ts except
for a few changes. The hepatoma cells were not transfected and were
90% confluent when stimulated. To obtain a strong signal, 2.5 nM of
hLIF or OSM were applied to the cells. The concentration of hLIF-05
was increased slightly to 625 nM. Rabbit anti-LIF-R-Fc was not co-
valently bound to the protein A- Sepharose, because coupling resulted
in higher backgrounds. Immunoprecipitated proteins were separated
on 7.5% gels.
RESULTS
hLIF-05 Antagonizes All LIF-R Ligands on Human Cell
Lines—Because hLIF-05 antagonized hLIF stimulated prolif-
eration of the Ba/F3-hLIF-R-hgp130 cell line (42), we tested
hLIF-05 for antagonism of hOSM. In the experiment shown, 15
nM hLIF-05 achieved 50% inhibition of hLIF (Fig. 1A), com-
pared with 10 nM for 50% inhibition of hOSM (Fig. 1B). Taking
into account that more hOSM was applied to reach the baseline
stimulation, the ratio of antagonist to agonist required for 50%
inhibition was higher for hLIF than for hOSM (10,000-fold
versus 200-fold). Full antagonism of both hLIF and hOSM was
achieved with ;100 nM hLIF-05. hLIF-05 showed no agonistic
activity, even at high concentrations. The ratio of antagonist to
agonist required for 50% inhibition varied within a 10-fold
range among experiments, according to the sensitivity of the
cells; higher ratios were required when the EC50 values for
hLIF and hOSM were lower (n 5 3). Nonetheless, hLIF-05 was
always more efficient at antagonizing hOSM than hLIF. The
antagonism by hLIF-05 could not be attributed to nonspecific
toxicity because it was easily overcome by higher agonist con-
centrations (Fig. 1, C and D). The observed shift in the dose-
response curve to higher concentrations of agonist in the pres-
ence of hLIF-05 is consistent with hLIF-05 competing with
hLIF for LIF-R occupancy.
A good test of the specificity of hLIF-05 for LIF-R is to
challenge hLIF-05 with the related OSM-R. The hepatoma cell
line HepG2 is well suited to this experiment because both
hOSM and hLIF elicit acute phase responses. The maximal
response to hOSM, however, is much greater than to hLIF, a
reflection of the greater number and/or potency of hOSM-R in2 K. R. Hudson, unpublished data.
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this cell line (10, 20, 53). mCT-1 and hCNTF/soluble CNTFRa
elicit maximal responses similar to those obtained with hLIF, a
result that is consistent with LIF-R dependence (data not
shown). CNTF on its own is effective only at 10,000-fold higher
concentrations (data not shown and Ref. 53).
As in the Ba/F3-hLIF-R-hgp130 cells, hLIF-05 antagonized
the response to hLIF in HepG2 cells (Fig. 2). Because hLIF
responses were relatively small, a maximal dose of hLIF (50
pM), which provided a robust response, was chosen for antago-
nism assays. The acute phase response was measured by hap-
toglobin accumulation in the culture supernatants. About 10
nM hLIF-05 (200-fold excess) was required for 50% inhibition of
the hLIF response and about 100 nM for full inhibition. hLIF-05
also antagonized mCT-1 and CNTF-soluble CNTFRa with 50%
inhibition at 10-fold lower concentrations of hLIF-05 than re-
quired for inhibition of hLIF. The lower concentrations of
hLIF-05 required may reflect a lower affinity of mCT-1 for
hLIFR-hgp130 and limitations of adding soluble CNTFRa. In
contrast, hLIF-05 did not significantly diminish responses to
hOSM or hIL-6 (Fig. 2). The failure to inhibit hOSM and hIL-6
demonstrates that hLIF-05 is specific for LIF-R. Including
hLIF-05 throughout the dose-response curves for IL-6 and
OSM also failed to reveal inhibition (data not shown). hLIF-05
on its own did not stimulate an acute phase response.
CNTFRa-mediated responses are likely to be an important
subset of LIF-R responses, to judge by the similar phenotypes
observed in CNTFRa2/2 and LIF-R2/2 mice (23, 24). In many
neurons, LIF-R ligands stimulate the production of vasoactive
intestinal polypeptide (VIP) (35, 59, 60), a neuropeptide that
may serve as an autocrine growth factor (61). hLIF-05 was
tested for inhibition of VIP induction in IMR 32, a human
neuroblastoma cell line that makes glycosylphosphatidylinosi-
tol-linked CNTFRa. hLIF-05 inhibited VIP induction by both
hLIF (Fig. 3A) and hOSM (Fig. 3B). CNTF responses were also
antagonized but only to a modest extent (Fig. 3C).
hLIF-05 Blocks LIFR-gp130 Phosphorylation—The biologi-
cal assays described above measure downstream responses
occurring over a 24–72-h incubation period. Measuring recep-
tor phosphorylation provides a more direct assessment of re-
ceptor activation. Receptor tyrosine phosphorylation was as-
sayed in 293T cells transfected with hgp130 and hLIF-R. The
cells were stimulated with hLIF in the presence or the absence
of an excess of hLIF-05. Receptors were immunoprecipitated
from cell lysates with anti-LIF-R or anti-gp130 antibodies and
then immunoblotted and probed with anti-phosphotyrosine an-
tibodies. Exposing the cells to hLIF resulted in the tyrosine
phosphorylation of LIF-R (190 kDa; top left, Fig. 4A). The
smaller protein (145 kDa) that co-immunoprecipitated is likely
to be tyrosine phosphorylated gp130 because the protein co-
migrated with the major component immunoprecipitated by
the anti-gp130 antibodies. Including an excess of hLIF-05
blocked the majority of the tyrosine phosphorylation of LIF-R.
No phosphorylated LIF-R was observed in response to hLIF-05
alone (top left, Fig. 4A). As in the case of LIF-R, gp130 was
tyrosine phosphorylated in response to hLIF (145 kDa; top
right, Fig. 4A). A small amount of phosphorylated LIF-R (190
FIG. 2. The production of haptoglobin by HepG2 cells in re-
sponse to hLIF, mCT-1, and hCNTF-CNTFRa is inhibited by
hLIF-05 but not the response to hIL-6 or hOSM. A constant con-
centration of agonist (50 pM) was applied in the presence or the absence
of increasing concentrations of hLIF-05. CNTFRa was applied as a
40-fold dilution of serum-free culture medium containing c-myc tagged
soluble CNTFRa. Results are expressed as a ratio of haptoglobin pro-
duced in the presence of hLIF-05 divided by the haptoglobin produced in
the absence. Values represent the mean of three independent experi-
ments. The S.E. of the mean was less than 15%. l, hLIF; , mCT-1; ,
hCNTF-CNTFRa; , IL-6; f, hOSM.
FIG. 1. The proliferation of the Ba/
F3-hLIF-R-hgp130 cell line in re-
sponse to hLIF and hOSM is inhib-
ited by hLIF-05. A constant
concentration of agonist was applied in
the presence (filled symbols) or the ab-
sence (open symbols) of increasing concen-
trations of hLIF-05. A, hLIF (1.5 pm). B,
hOSM (50 pM). The antagonism is over-
come by increasing concentrations of ago-
nist. Agonist was titrated in the presence
(filled symbols) or absence (open symbols)
of a constant concentration of hLIF-05
(54.5 nM). C, hLIF. D, hOSM. Results are
expressed as the A570 value of cells as-
sayed for proliferation by 3-(4,5-dimethyl
thiazol-2yl)-2,5-diphenyl tetrazolium bro-
mide. Values represent the mean of trip-
licate samples. The S.E. for all points was
less than 10% of the mean.
A LIF-R Antagonist for LIF, CT-1, CNTF, and OSM 26949
 at A
STO
N
 U
N
IV
ERSITY
 on M
arch 20, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
kDa) was co-immunoprecipitated. Stimulation with hLIF and
an excess of hLIF-05 blocked the tyrosine phosphorylation of
gp130. hLIF-05 on its own did not result in detectable phos-
phorylation of gp130 (top right, Fig. 4A). Similar quantities of
receptors were recovered in each immunoprecipitation, as evi-
denced by the signals observed when portions of the immuno-
precipitates were probed for LIF-R or gp130 (bottom half, Fig.
4A).
Receptor phosphorylation was next measured in HepG2 cells
because they present both LIF-R and OSM-R. As in the trans-
fected 293T cells, stimulating HepG2 cells with hLIF and im-
munoprecipitating receptors with anti-LIF-R antibodies re-
vealed tyrosine phosphorylated LIF-R (190 kDa) and co-
immunoprecipitated tyrosine phosphorylated gp130 (155 kDa
in HepG2s). Excess hLIF-05 was able to block the majority of
the tyrosine phosphorylation of LIF-R (left side, Fig. 4B). Stim-
ulation by OSM also resulted in the appearance of tyrosine
phosphorylated LIF-R. Very little gp130 was co-immunopre-
cipitated, a result that perhaps reflects a faster dissociation of
the OSM-LIF-R-gp130 complex. As for hLIF, an excess of
hLIF-05 blocked the phosphorylation of LIF-R stimulated by
OSM (left side, Fig. 4B). The receptors immunoprecipitated by
the anti-gp130 antibodies proved more revealing. hLIF stimu-
lated the tyrosine phosphorylation of gp130 (155 kDa) and a
small amount of co-immunoprecipitated LIF-R (190 kDa).
Again, the phosphorylations were blocked by an excess of hLIF-
05. hOSM also stimulated the phosphorylation of gp130 (155
kDa). However, hLIF-05 did not block the phosphorylation of
gp130 stimulated by OSM (right side, Fig. 4B), despite having
blocked the phosphorylation of LIF-R by OSM. The failure to
block agrees with the Ba/F3-hLIF-R-hgp130 and HepG2 bioas-
says above, which demonstrated that hLIF-05 blocks OSM
responses mediated by LIF-R-gp130 but not those mediated by
OSM-R-gp130.
FIG. 3. The induction of VIP expression by IMR 32 cells in
response to hLIF, hOSM, and hCNTF is inhibited by hLIF-05.
Agonist was titrated in the presence (filled symbols) or absence (open
symbols) of a constant concentration of hLIF-05 (100 nM). A, hLIF. B,
hOSM. C, hCNTF. IMR32 cells were co-transfected with VIPCAT1 and
Rous sarcoma virus-b-Gal, stimulated with cytokines, and assayed for
reporter expression. Results are presented as the ratio of chloramphen-
icol acetyltransferase expressed under the control of the VIP promoter
to b-Gal expressed under the Rous sarcoma virus promoter. Chloram-
phenicol acetyltransferase and b-Gal were measured by enzyme-linked
immunosorbent assay. One of two experiments is shown.
FIG. 4. Receptor phosphorylation is inhibited by hLIF-05.
293Ts transfected with LIF-R and gp130 (A) were incubated for 15 min
in the absence (–) or in the presence of hLIF (LIF), hLIF-05 (05), or
hLIF1hLIF-05 (LIF/05) at the concentrations indicated under “Exper-
imental Procedures.” HepG2s (B) were also stimulated with OSM or
OSM1hLIF-05 (OSM/05). Cells were lysed with Nonidet P-40, and the
lysates were immunoprecipitated with anti-LIF-R antibodies (left-hand
side) or anti-gp130 (right-hand side). Immunoprecipitates were sepa-
rated by SDS-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membrane. Immunoblots were probed with
the following antibodies. A (top row) and B, anti-phosphotyrosine. A
(bottom left), anti-LIF-R. A (bottom right), anti-gp130. LIF-R is posi-
tioned at 190 kDa. gp130 is positioned at 145 (A) or 155 kDa (B).
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DISCUSSION
Antagonists for a variety of four-helical bundle cytokines
have been created by allowing high affinity binding to the first
receptor subunit while destroying low affinity binding to a
sequentially assembled receptor subunit. Examples include
both homodimerizing ligands such as growth hormone (62) and
hetero-oligomerizing ligands such as IL-4 (63), or granulocyte
macrophage colony stimulating factor (64). Within the sub-
group of gp130-dependent cytokines, IL-6 antagonists with re-
duced binding to gp130 (65, 66) and CNTF antagonists with
reduced binding to LIF-R (67) have been described. IL-6 and
CNTF antagonists show narrow specificities because the an-
tagonists retain binding to their respective specificity subunits
but do not sequester shared subunits (68). The broad specificity
of hLIF-05 makes it a novel reagent for this family.
The high ratio of hLIF-05 to LIF-R ligand required for effec-
tive antagonism is not unusual. Although the EC50 for hLIF
varied on Ba/F3-hLIF-R-hgp130, the average was 2.5 pM (n 5
12), making the cells as sensitive as XG-1 myeloma cells, which
have been used as a rigorous test for residual agonism in IL-6
antagonists (68). The ratios reported here for Ba/F3-hLIF-R-
hgp130 are similar to those required of IL-6 antagonists with
reduced gp130 binding (68, 69). Subsequently, IL-6 antagonists
with very high potency were obtained by adding mutations that
enhance IL-6 receptor binding (65, 66, 69). A similar strategy
may be applicable to hLIF-05.
The EC50 for hLIF on HepG2s (3–4 pM) was within the range
observed for Ba/F3-hLIF-R-hgp130 cells, yet a much lower ratio
of antagonist to agonist was required for inhibiting hLIF re-
sponses on HepG2 cells. Similar cell type-dependent potencies
have been documented for other cytokine antagonists (64, 69).
The complete sparing of the OSM response in HepG2s suggests
that activating OSM-R is sufficient for the acute phase re-
sponse. HepG2 cells may form three times as many OSM-R-
gp130 complexes as LIF-R-gp130 complexes (10). Further ex-
periments with hLIF-05 on cell types that are limiting in
OSM-R might reveal situations in which both OSM-R and
LIF-R are needed for a full response.
Although many cytokine antagonists have been described,
the immediate receptor events have rarely been documented. A
murine IL-4 antagonist has been shown to inhibit the tyrosine
phosphorylation of JAK3 and STAT6 in Ba/F3 cells (70). LIF-R
and gp130 each has five tyrosine-based motifs that are distal to
the membrane-proximal Jak binding domain (71). The most
distal four of gp130 and the most distal three of LIF-R are all
capable of mediating STAT3 tyrosine phosphorylation (71). As
demonstrated here, hLIF-05 inhibits the tyrosine phosphoryl-
ation of LIF-R and gp130, so hLIF-05 will block STAT3 recruit-
ment, activation by phosphorylation, and translocation to the
nucleus. Blocking STAT3 activation fits with the antagonism
observed in both HepG2 and IMR 32 cells. STAT3 plays a key
role in the acute phase response, including the stimulation of
haptoglobin expression (17, 72) and in the induction of VIP by
LIF-R ligands (73). Altbough we cannot rule out receptor-phos-
phorylation-independent signaling, the lack of any detectable
agonism by hLIF-05 in the three cell types examined argues
that hLIF-05 does not itself activate primary signal transduc-
tion pathways. The inhibition of receptor phosphorylation fur-
ther demonstrates that hLIF-05 prevents activation of a major
signal transduction pathway for LIF-R ligands and is consist-
ent with a block in receptor hetero-oligomerization.
The broad specificity of hLIF-05 and its lack of intrinsic
signaling make hLIF-05 a powerful reagent. As for other solu-
ble antagonists, tailoring the dosage of hLIF-05 for a particular
cell type allows flexibility in setting the degree of inhibition.
hLIF-05 has been used successfully to demonstrate that LIF-R
activation is required for the arrest of rod differentiation in
cultures of mouse retinal cells (74). In the future, hLIF-05 may
prove useful in defining a role for LIF-R in receptor complexes
for newly identified ligands. Antagonists specific to IL-4 recep-
tor a also antagonized IL-13 responses, revealing receptor sub-
units shared between IL-4 and IL-13 (63, 75, 76). Application of
hLIF-05 should lead to a better understanding of the role of
LIF-R in a variety of homeostatic and disease processes.
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